Aurora Cannabis Inc (ACB) is a well-known company in the global cannabis industry, operating across 25 countries. Headquartered in Edmonton, Alberta, Canada, the company is publicly traded on the Toronto Stock Exchange and the New York Stock Exchange since October 2018. ACB is committed to setting the highest standards for product quality, client services, and innovative developments within this burgeoning industry.
Aurora specializes in the production and distribution of medical cannabis, with a broad and extensive product portfolio that includes dried cannabis, cannabis oil, softgels, oral dissolvable wafers, vaporizer, and topicals. The company’s products are designed to serve an array of cannabis markets, including medical patients, adult-use consumers, and wellness-focused consumers.
ACB's medical cannabis business is its core strength, recognized by physician and patient communities worldwide. It has a robust medical research strategy, partnering with globally acclaimed research-focused organizations, resulting in several initiated clinical trials and case studies with the goal of advancing knowledge of cannabinoids as medically therapeutic solutions.
Aurora is serving the consumer market under numerous well-reputed brands that cater to an array of consumer preferences. Since the legalization of recreational cannabis in Canada in October 2018, Aurora has proven itself as a dominant player in this market segment as well.
Aside from its primary business activities, ACB is also committed to sustainability and community engagement. The company operates with an environmentally friendly approach, using purpose-built indoor cannabis facilities with advanced climate control systems that reduce waste and energy usage. Aurora frequently gives back to the communities in which it operates, notably through job creation, investing in local infrastructure, and supporting local charities and non-profit organizations.
However, the rapid growth and regulatory changes in the cannabis industry have given rise to challenges for most cannabis companies including ACB. Slower than expected retail rollouts and over-supply situations have affected the sales and profitability of the industry, leading to a downturn in Aurora’s stock prices.
Despite these challenges, Aurora Cannabis Inc continues to shape the future of cannabis as a leading player in this growing sector - building high-quality cannabis products, investing in research and development, and generating significant employment to create a robust and sustainable industry.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Zacks Equity Research has named Aurora Cannabis (ACB) as its Bull of the Day due to improved business focus on high-margin global medical cannabis, rising earnings estimates, and strengthening technicals. Conversely, Baidu (BIDU) is the Bear of the Day because of struggles in its legacy operations, persistent decline in online marketing revenue, and sharply falling earnings estimates despite investments in AI and autonomous driving. The article also touches upon PepsiCo's (PEP) strategy with zero-sugar drinks and compares it with Coca-Cola (KO) and Monster Beverage (MNST).

Aurora Cannabis Inc. (TSX:ACB) has provided an update focusing on its international medical cannabis expansion and its response to Curaleaf's pending offer. This development keeps Aurora Cannabis relevant in the Canadian cannabis sector, with the article emphasizing that the company's ability to convert this announcement into operational progress will be key. The ongoing narrative for Aurora and its peers will depend on consistent execution, timely updates, and how these align with broader sector trends.

Aurora Cannabis has rejected Curaleaf's latest application to halt its at-the-market (ATM) program, calling it a "desperate" attempt to divert attention from an inadequate hostile bid. Aurora asserts that Curaleaf's bid undervalues the company's assets and future potential, especially given Curaleaf's significant debt compared to Aurora's debt-free position. The company's board unanimously recommends shareholders reject Curaleaf's offer, emphasizing that the ATM program was established for long-term growth, not as a response to the hostile takeover.

Curaleaf Holdings is actively urging Aurora Cannabis shareholders to accept its takeover offer after Aurora's board declined the proposal. The offer values Aurora shares at $4.00, representing a 45% premium, and Curaleaf projects significant annual synergies and combined revenue of over $1.5 billion. Curaleaf highlighted Aurora's recent financial underperformance to support its case for the acquisition, with a tender offer deadline set for December 1, 2026.

Aurora Cannabis Inc. has appointed Faris El Refaie as Executive Vice President, Global Commercial, a newly created role. El Refaie brings 25 years of biopharmaceutical experience and will be responsible for Aurora's global commercial function, including medical cannabis market strategy and expanding commercial capabilities internationally. His appointment aims to strengthen Aurora's global footprint and customer engagement.